Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Equity Ratio (2019 - 2025)

Historic Equity Ratio for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to 0.46.

  • Madrigal Pharmaceuticals' Equity Ratio fell 3657.44% to 0.46 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.46, marking a year-over-year decrease of 3657.44%. This contributed to the annual value of 0.72 for FY2024, which is 1438.27% up from last year.
  • Madrigal Pharmaceuticals' Equity Ratio amounted to 0.46 in Q3 2025, which was down 3657.44% from 0.69 recorded in Q2 2025.
  • Madrigal Pharmaceuticals' 5-year Equity Ratio high stood at 0.84 for Q1 2021, and its period low was 0.07 during Q3 2022.
  • Moreover, its 5-year median value for Equity Ratio was 0.69 (2025), whereas its average is 0.59.
  • Its Equity Ratio has fluctuated over the past 5 years, first plummeted by 9127.51% in 2022, then surged by 67446.44% in 2024.
  • Madrigal Pharmaceuticals' Equity Ratio (Quarter) stood at 0.72 in 2021, then dropped by 24.12% to 0.54 in 2022, then grew by 16.23% to 0.63 in 2023, then grew by 14.38% to 0.72 in 2024, then plummeted by 36.55% to 0.46 in 2025.
  • Its Equity Ratio stands at 0.46 for Q3 2025, versus 0.69 for Q2 2025 and 0.71 for Q1 2025.